Technical University of Munich

Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board

Retrieved on: 
수요일, 3월 1, 2023
Genetics, Stanford University, Pediatrics, Therapy, Cancer, MBBS, University, Rare, SAB, Molecular medicine, Technical University of Munich, Life, Drug development, Assistant, Patient, SAN, Institute of technology, Genetic engineering, Haemophilia A, Gene editing, Gene, George Church (geneticist), Pharmaceutical industry, Medical device, Vaccine, Phenylketonuria

SAN DIEGO, March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB).
  • These world-class researchers will join George M. Church, Ph.D., Chair of Poseida's recently formed Gene Therapy SAB, to provide counsel on the Company's gene therapy programs in development.
  • Brent Warner, President of Gene Therapy at Poseida, added: "We are pleased to round out our Gene Therapy SAB as we enter a pivotal moment in the preclinical development of our gene therapy programs for rare diseases with urgent unmet need.
  • "The promise of gene therapy and gene editing is emerging as one of the most exciting areas of drug development today," said Dr. Church.

Classiq Collaborates With Microsoft to Bring Advanced Quantum Software to Researchers and Academic Institutions

Retrieved on: 
수요일, 2월 8, 2023
Apps, Applications, Technology, Other Technology, Software, Networks, Internet, Hardware, Technical University of Munich, Automation, Organization, Quantum, Samsung, University, NTT, Computer, Intesa Sanpaolo, Microsoft, Entrepreneurship, Lagos State Ministry of Finance, HSBC, Research, Microsoft Azure, School, Science, Student, Education, Bangladesh Technical Education Board, Institute of technology, Multimedia, HPE, Video game, Television, Microscope

Classiq today launched a global program for quantum software research and education, dedicated to universities and educational institutions offering Classiq’s advanced quantum computing platform and Microsoft Azure Quantum’s cloud access to quantum computers.

Key Points: 
  • Classiq today launched a global program for quantum software research and education, dedicated to universities and educational institutions offering Classiq’s advanced quantum computing platform and Microsoft Azure Quantum’s cloud access to quantum computers.
  • View the full release here: https://www.businesswire.com/news/home/20230208005137/en/
    Classiq Collaborates With Microsoft to Bring Advanced Quantum Software to Researchers and Academic Institutions (Graphic: Business Wire)
    The classiq.io/academia offering, already used by leading universities, targets two major goals:
    Accelerating quantum software education by providing an advanced platform for automated quantum software design and execution.
  • Advancing quantum computing by giving researchers a scalable, robust quantum software design platform with seamless access to computation.
  • The companies’ quantum stack brings quantum computing software closer to the vision presented by Microsoft in its 2020 Nature paper “Quantum Programming Languages.”
    Classiq's platform is already used by leading universities in quantum computing courses and research.

Pediatric Investigation Review Throws Light on Improving Diagnosis of Genetic Diseases with RNA Sequencing

Retrieved on: 
수요일, 2월 8, 2023
DNA, Blood, Fibroblast, Diagnosis, NGS, Tissue, DSM-IV codes, WGS, Cell, RNA, Transcriptome, Proteomics, WES, Institute of technology, Technical University of Munich, Genetic disorder, Genome, Gene expression, Vaccine, Medical imaging

BEIJING, Feb. 8, 2023 /PRNewswire/ -- The use of next-generation sequencing (NGS) has simplified the diagnosis of human genetic disorders.

Key Points: 
  • BEIJING, Feb. 8, 2023 /PRNewswire/ -- The use of next-generation sequencing (NGS) has simplified the diagnosis of human genetic disorders.
  • Since the mapping of the human genome, scientists have been able to detect diseases even at a "single gene" level.
  • Also, NGS techniques like whole-exome sequencing (WES) and whole-genome sequencing (WGS) are unable to determine the cause of several genetic disorders.
  • In their article, the researchers analyzed eight previous studies and found a 15% improvement in the performance of DNA-based sequencing when combined with RNA sequencing.

Repligen Appoints Martin D. Madaus to Board of Directors

Retrieved on: 
목요일, 2월 9, 2023
Repligen Corporation Award in Chemistry of Biological Processes, Aptitude, Merck Millipore, Repligen, Ortho Clinical Diagnostics, Martin, Acquisition, Merck Group, The Carlyle Group, Veterinary medicine, Technical University of Munich, University, Lead, Covidien, AG, Growth, Doctor of Philosophy, Management

WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.

Key Points: 
  • WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus.
  • He is an active board leader, currently serving two public companies; as Lead Director for precision health technology company Quanterix Corporation and as Board member for mass cytometry player Standard BioTools, Inc. (previously Fluidigm Corporation).
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We are thrilled to welcome Dr. Madaus to the Repligen board, as the company continues to drive innovation in bioprocessing and expand into new markets.
  • Hunt, President and Chief Executive Officer said, “I’m excited for this opportunity to work more closely with Martin.

Proteinea announces release of 'Ankh' the world's top performing protein language model, a major step forward for A.I based protein engineering and drug development

Retrieved on: 
화요일, 1월 17, 2023
Institute of technology, KAUST, Technical University of Munich, Biomedical engineering, Molecular biology, TPU, Computational biology, Sota, Protein engineering, A-DNA, Drug design, Fine chemical, Ankh

NEWTON, Mass., Jan. 17, 2023 /PRNewswire/ -- Proteinea, a biotech startup pioneering computational protein engineering technologies, announces today the open-source release of Ankh; the world's top performing protein language model.

Key Points: 
  • NEWTON, Mass., Jan. 17, 2023 /PRNewswire/ -- Proteinea, a biotech startup pioneering computational protein engineering technologies, announces today the open-source release of Ankh; the world's top performing protein language model.
  • Protein language models are the basis of A.I/Deep learning based protein engineering and drug design.
  • With Ankh, Proteinea is actively seeking new partners and collaborators to utilize the model for further innovation in protein engineering & biotherapeutics development.
  • At Proteinea the goal is to push the boundaries of protein engineering and deliver direct value through rapid and reliable development capabilities.

The Most Prominent Conference on Educational Innovation in the Spanish-Speaking World, CIIE 2023 Begins

Retrieved on: 
월요일, 1월 16, 2023
Associate, Partner, Social media, University, Education, Science and technology in Asia, Learning, Futures of Education, Entrepreneurship, Society, Secretary of State for Trade and Industry v Bottrill, UNESCO Institute for Lifelong Learning, Tecnológico de Monterrey, Campus Santa Fe, Government, UNESCO International Institute for Educational Planning, Technical University of Munich, Future, Knowledge, Dean (education), Singularity University, Conference, STEM, Engineering, UNESCO, Research, Spokesperson, Information Systems International Conference, Lifelong learning, Georgia Tech, School of Educational Innovation and Teacher Preparation, Monterrey Institute of Technology and Higher Education, Management, Creative industries, Health

MONTERREY, Mexico, Jan. 16, 2023 /PRNewswire/ -- The 9th International Conference on Educational Innovation (CIIE 2023) will take place in the Tecnológico de Monterrey, Monterrey Campus, from January 16–18.

Key Points: 
  • MONTERREY, Mexico, Jan. 16, 2023 /PRNewswire/ -- The 9th International Conference on Educational Innovation (CIIE 2023) will take place in the Tecnológico de Monterrey, Monterrey Campus, from January 16–18.
  • Tecnológico de Monterrey's Institute for the Future of Education Executive Director, Michael Fung, delivered the keynote address "Transforming Higher Education and Lifelong Learning" as part of the opening ceremony.
  • More than 722 proposals were submitted for this Conference's edition, focusing on six thematic tracks: Educational Innovation, Educational Technologies, Lifelong Learning, Academic Innovation in Health, Edtech Entrepreneurship and Educational Innovation Management.
  • More than 500 experiences on educational innovation are available at CIIE 2023, including presentations of research and innovation papers, panels, book presentations, workshops, networking opportunities and poster sessions by educators and experts from different countries around the world.

Lilium Appoints Oliver Vogelgesang as Chief Financial Officer and Sebastien Borel as Chief Commercial Officer

Retrieved on: 
월요일, 1월 16, 2023
Honeywell, Airbus A320 family, University, Technical University of Munich, Klaus, Aviation, CFO, Aircraft, CCO, ESG, Microsoft, Program management, MBA, A320, Management, Airline, Finance, Lilium, Airbus

MUNICH, Germany, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, announced today that the Board of Directors has appointed Oliver Vogelgesang as Chief Financial Officer (CFO) and Sebastien Borel as Chief Commercial Officer (CCO) with immediate effect.

Key Points: 
  • MUNICH, Germany, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, announced today that the Board of Directors has appointed Oliver Vogelgesang as Chief Financial Officer (CFO) and Sebastien Borel as Chief Commercial Officer (CCO) with immediate effect.
  • Oliver Vogelgesang will take over from Geoffrey Richardson, who is stepping down following a successful tenure, including bringing Lilium through a listing on NASDAQ.
  • Oliver joined Lilium in July 2021 as SVP Finance & Controlling, tasked with building the Controlling and Investor Relations functions.
  • Sebastien joined Lilium in November 2021 as Vice President Business and was appointed SVP Commercial in April 2022.

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

Retrieved on: 
목요일, 12월 1, 2022
Biotechnology, Health, General Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Associate professor, Prostate cancer, Safety, Radiopharmaceutical, CEUS, Cancer, PET, Regulation of tobacco by the U.S. Food and Drug Administration, Magnetic resonance, University, PLN, Health, Therapy, Trial of the century, RP, MD Anderson Cancer Center, MRI, Cardiac catheterization, Prostate, Multimedia, Acquisition, New Drug Application, Technical University of Munich, Interventional radiology, CT, Google Images, MD, Dissection, Institute of technology, Molecular imaging, Recurrence, Nuclear medicine, SUO, Magnetic resonance imaging, Food, Precision medicine, EAP, 3D ultrasound, Division, Prognosis, Isotope, PSMA, Membrane, Risk, Medical imaging, Patient

The Phase 3 LIGHTHOUSE clinical study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a decision-making aid in assessing newly diagnosed prostate cancer in patients with unfavorable intermediate-, high- or very high-risk disease.

Key Points: 
  • The Phase 3 LIGHTHOUSE clinical study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a decision-making aid in assessing newly diagnosed prostate cancer in patients with unfavorable intermediate-, high- or very high-risk disease.
  • The LIGHTHOUSE Phase 3 clinical trial was a prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of 18F-rhPSMA-7.3 Positron Emission Tomography (PET) in men with newly diagnosed prostate cancer.
  • Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies.

Study Shows What Soccer Can Teach Managers About Hiring Top Talent

Retrieved on: 
수요일, 11월 30, 2022
Doctor of Philosophy, Psychology, University, Social support, College Park, Institute of technology, Smith School, MBA, Education, School, Journal, Robert H. Smith School of Business, University of Maryland, College Park, Thought, Research, Sport, Business, Technical University of Munich, Video game, Creative industries, Management

"Companies are always interested in hiring new talent, particularly high-end talent," Chen says.

Key Points: 
  • "Companies are always interested in hiring new talent, particularly high-end talent," Chen says.
  • They looked at European soccer leagues, where player stats are analyzed in online databases to determine an individual player's worth.
  • Here's where it gets a little complicated in soccer: Lower performing teams often have less money to spend on top talent.
  • You'll get bigger benefits versus hiring them in the middle of the season, where you may hurt the team.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Retrieved on: 
화요일, 11월 29, 2022
BRCA, Genomics, Health, Risk, CST, MYGN, Precision medicine, Recurrence, SALT, Myriad Genetics, Genetics, Patient, Myriad, Sumathi Best Television Current Reporting Award, Association for Molecular Pathology v. Myriad Genetics, Inc., Technical University of Munich, BRCA1, FDA, BRCA2, Diagnosis, Physician, Berlin, Prequel, Risk assessment, News, Genetic testing, HRD, Breast cancer, PRS, Institute of technology, University, Cancer, Woman, HIV disease progression rates, Birth control, Pharmaceutical industry, Medical imaging

SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.

Key Points: 
  • SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc ., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
  • The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer.
  • Among the Myriad products highlighted in the companys SABCS exhibit are:
    MyRisk with RiskScore , Myriads market-leading hereditary cancer test that offers the first polygenic breast cancer risk assessment for women of all ancestries.
  • RiskScore delivers a personalized 5-year and lifetime risk for developing breast cancer for women who qualify for MyRisk.